Clinical Trial Details

< Previous Trial     Next Trial >
Study ID 000033
Investigator
William Dahut,   National Cancer Institute (NCI)
Title Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
Conditions Stage IV Prostate Cancer
Adenocarcinoma of the Prostate
Recurrent Prostate Cancer
Interventions Drug: docetaxel
Drug: thalidomide
Phase Phase 2
Purpose RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of prostate cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase II trial to compare the effectiveness of docetaxel with or without thalidomide in treating patients who have metastatic prostate cancer.
Eligibility Ages Eligible: 18 Years
Genders Eligible:  Both
Accepts Healthy Volunteers: 
Study Location
Contact

Information objtained from ClinicalTrials.gov, on 7/24/2014. For additional information about this and other clinical trials, visit http://clinicaltrials.gov.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00020046


Back to Search Results